Comparative clinical effects and cost-effectiveness of maximum androgen blockade, docetaxel with androgen deprivation therapy and ADT alone for the treatment of mHSPC in China.
J Comp Eff Res
; 8(11): 865-877, 2019 08.
Article
em En
| MEDLINE
| ID: mdl-31476895
ABSTRACT
Aim:
To compare the clinical effects and cost-effectiveness of maximum androgen blockade (MAB), docetaxel to androgen deprivation therapy (Doc-ADT) and ADT alone for the treatment of patients with metastatic hormone-sensitive prostate cancer in China.Methods:
A network meta-analysis and a Markov model were adopted for effectiveness and economic evaluation.Results:
The hazard ratios of overall survival and progression-free survival were 0.782 and 0.628 for Doc-ADT versus ADT alone; 0.897 and 0.824 for MAB versus ADT alone. Doc-ADT was cost-effective compared with MAB and ADT alone, with an incremental cost-effectiveness ratio of CNY 96,848 and CNY 67,758 per quality-adjusted life year, respectively. MAB was cost-effective compared with ADT alone, with an incremental cost-effectiveness ratio of CNY 137,487 per quality-adjusted life year.Conclusion:
Doc-ADT is likely the optimal option from the perspective of both clinical outcomes and economic considerations.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Contexto em Saúde:
1_ASSA2030
/
6_ODS3_enfermedades_notrasmisibles
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Próstata
/
Docetaxel
/
Antagonistas de Androgênios
Tipo de estudo:
Clinical_trials
/
Health_economic_evaluation
/
Systematic_reviews
Aspecto:
Patient_preference
Limite:
Humans
/
Male
País/Região como assunto:
Asia
Idioma:
En
Revista:
J Comp Eff Res
Ano de publicação:
2019
Tipo de documento:
Article